An Italian programme for COVID-19 infection in multiple sclerosis
Maria Pia Sormani
Abstract
Italy was the first European country to encounter the effects of the coronavirus disease 2019 (COVID-19) pandemic.1 For people with multiple sclerosis, the situation carries additional reasons for concern. Although emerging work suggests that some coexisting diseases, such as hypertension, might increase the severity of the COVID-19 infection, how less common conditions, such as multiple sclerosis, effect COVID-19 outcomes is still uncertain. Furthermore, immunosuppressive therapies, the mainstay of treatment for multiple sclerosis, might confer additional risks or, on the contrary, confer some protection.
Topics & Concepts
Coronavirus disease 2019 (COVID-19)Multiple sclerosisSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2019-20 coronavirus outbreakVirologyBetacoronavirusCoronavirus InfectionsMedicineMEDLINEBiologyOutbreakImmunologyInternal medicineInfectious disease (medical specialty)DiseaseBiochemistrySARS-CoV-2 and COVID-19 ResearchCOVID-19 epidemiological studiesZoonotic diseases and public health